Denali Therapeutics (DNLI) Receivables - Net (2018 - 2026)

Denali Therapeutics has reported Receivables - Net over the past 8 years, most recently at $2.2 million for Q4 2025.

  • Quarterly Receivables - Net changed 0.28% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, changed 0.28% year-over-year, with the annual reading at $2.2 million for FY2025, 0.28% changed from the prior year.
  • Receivables - Net was $2.2 million for Q4 2025 at Denali Therapeutics, up from $1.9 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $15.0 million in Q2 2021 and troughed at $1.4 million in Q2 2024.
  • The 5-year median for Receivables - Net is $2.1 million (2023), against an average of $3.6 million.
  • Year-over-year, Receivables - Net soared 4900.0% in 2021 and then plummeted 70.91% in 2023.
  • A 5-year view of Receivables - Net shows it stood at $15.0 million in 2021, then crashed by 38.12% to $9.3 million in 2022, then tumbled by 70.91% to $2.7 million in 2023, then fell by 19.59% to $2.2 million in 2024, then increased by 0.28% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Receivables - Net are $2.2 million (Q4 2025), $1.9 million (Q3 2025), and $1.4 million (Q2 2025).